- $106.34bn
- $123.47bn
- €46.72bn
EU regulator backs Sanofi's injectable version of blood cancer drug
Brief: Sanofi’s Sarclisa Subcutaneous Formulation Via On-Body Injector Recommended For EU Approval
US Senators reach deal on capping insulin costs at $35 per month, Semafor reports
Brief: Sanofi And Regeneron's Dupixent Approved To Treat Bullous PEMPHIGOID In Japan
Kali Therapeutics signs deal with Sanofi to develop autoimmune treatment
Sanofi launches innovation and operation centre in China
Analysis: TrumpRx lists many medicines at prices higher than paid in UK
Brief: Sanofi: Venglustat Earns Breakthrough Therapy Designation In U.S.
Big drugmakers must face US overcharge claims on medications for low-income patients
US judge blocks efforts to reshape childhood vaccine policy (updated)
US judge blocks efforts to reshape childhood vaccine policy
Brazil drugmaker EMS eyes overseas deals after buying Sanofi unit
MS cuts Grifols to 'equal-weight' amid revenue growth uncertainties
Factbox: Global drugmakers rush to boost US presence as tariff threat looms
Deals of the day-Mergers and acquisitions
Brazil's EMS purchases Sanofi's Medley in deal worth over $500 million (updated)
Deals of the day-Mergers and acquisitions
Brazil's EMS purchases Sanofi's Medley
Sino Biopharm unit licenses blood cancer drug to Sanofi for up to $1.53 bln